Abstract: The present invention provides compositions comprising an effective amount of a peptide having the amino acid sequence Gly-Gly-(d)Val-(d)Leu-(d)Val-(d)Gln-(d)Pro-Gly (SEQ ID NO: 6) to promote tight junction integrity, or a pharmaceutically acceptable salt thereof, and a pharmaceutically-acceptable carrier. The present invention further provides methods of using the larazotide derivative compositions for promoting tight junction integrity in patients in need thereof.

Abstract: The present invention provides methods for treating disorders associated with intestinal barrier dysfunction and increased intestinal permeability. The invention involves administering an effective amount larazotide or a larazotide derivative to a subject or a patient in need thereof.

Abstract: The present invention provides methods for treating disorders associated with intestinal barrier dysfunction and increased intestinal permeability. The invention involves administering an effective amount larazotide or a larazotide derivative to a subject or a patient in need thereof.

Abstract: The present invention provides compositions and methods for treating or preventing gastrointestinal damage associated with acute or chronic non-steroidal anti-inflammatory drug (NSAID) therapy, including, for example, NSAID-induced gastropathy or enteropathy. In various embodiments, the invention relates to administering a regimen of larazotide (or a derivative) to a patient to repair or prevent injury to mucosal tissue of the gastrointestinal epithelium. In accordance with the invention, larazotide functions to repair injured mucosal tissue or prevent injury to mucosal tissue in a patient undergoing acute or chronic NSAID therapy.

Abstract: The present invention provides methods for treating disorders associated with intestinal barrier dysfunction and increased intestinal permeability. The invention involves administering an effective amount larazotide or a larazotide derivative to a subject or a patient in need thereof.

Abstract: Provided is a method for treating mucosal disorders using a specific prostaglandin compound. The prostaglandin compound induces a conformational change in the tight junction that results in recovery of mucosal barrier function. Accordingly, the prostaglandin compound used herein is useful for the treatment of mucosal disorders.